Varenicline (Chantix) Recall

Angie Szumlinski Announcements

On July 2, 2021, the U.S. Food and Drug Administration (FDA) issued an alert notifying patients and health care professionals to Pfizer’s voluntary recall of Varenicline, also known as Chantix. According to the alert, “the company is recalling varenicline because it may contain levels of a nitrosamine impurity, called N-nitroso-varenicline, above FDA’s acceptable intake limit. N-nitroso-varenicline may be associated with a potential increased cancer risk in humans, but there is no immediate risk to patients taking this medication.”

For more information, please read the full FDA release below:

FDA alerts health care professionals and patients to a voluntary recall of varenicline (Chantix) to the warehouse level